Literature DB >> 10419570

Microsurgical treatment of supratentorial cavernous malformations.

R G Ojemann1, C S Ogilvy.   

Abstract

The indications for the surgical management of supratentorial cavernous malformations are outlined and the results following operation are presented in this article. Surgery is indicated for most patients who present with seizures, neurologic deficit, or headache. The surgical approaches to lesions in the cerebrum are described. The operative morbidity and mortality are low. Over 95% of all patients have excellent or good results and return to their previous level of activity.

Entities:  

Mesh:

Year:  1999        PMID: 10419570

Source DB:  PubMed          Journal:  Neurosurg Clin N Am        ISSN: 1042-3680            Impact factor:   2.509


  4 in total

Review 1.  Cerebral Cavernous Malformation Pathogenesis: Investigating Lesion Formation and Progression with Animal Models.

Authors:  Chelsea M Phillips; Svetlana M Stamatovic; Richard F Keep; Anuska V Andjelkovic
Journal:  Int J Mol Sci       Date:  2022-04-30       Impact factor: 6.208

Review 2.  Rates and predictors of seizure freedom in resective epilepsy surgery: an update.

Authors:  Dario J Englot; Edward F Chang
Journal:  Neurosurg Rev       Date:  2014-02-05       Impact factor: 3.042

3.  Outcome after surgical or conservative management of cerebral cavernous malformations.

Authors:  Fiona Moultrie; Margaret A Horne; Colin B Josephson; Julie M Hall; Carl E Counsell; Jo J Bhattacharya; Vakis Papanastassiou; Robin J Sellar; Charles P Warlow; Gordon D Murray; Rustam Al-Shahi Salman
Journal:  Neurology       Date:  2014-07-03       Impact factor: 9.910

4.  Technical, Anatomical, and Functional Study after Removal of a Symptomatic Cavernous Angioma Located in Deep Wernicke's Territories with Cortico-Subcortical Awake Mapping.

Authors:  Silvio Sarubbo; Gianpaolo Basso; Franco Chioffi; Edward Cesnik; Beatrice Paradiso; Enrico Grandi; Enrico Fainardi; Valeria Tugnoli; Marco Farneti; Enrico Granieri
Journal:  Case Rep Neurol Med       Date:  2013-06-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.